ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/bispecific-PD-1/LAG3-antibody
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/bispecific-PD-1/LAG3-antibody
8
trial(s) found.
NCT05908786
Curative
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC) (
GO44457
)
Atezolizumab
Bevacizumab
Tiragolumab
Tobemstomig
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ bispecific PD-1/LAG3 antibody
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04524871
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (
Morpheus-Liver
)
ADG126
Atezolizumab
Bevacizumab
HIF2a inhibitor
NKT2152
PPAR-alpha inhibitor
TPST-1120
Tiragolumab
Tobemstomig
Tocilizumab
anti-CTLA-4 monoclonal antibody
anti-IL-6 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,HIF2a-targeting
cancer therapy,IL-6-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PPAR-alpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ bispecific PD-1/LAG3 antibody
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05852691
Advanced
Phase 2
Active not recruiting
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (
CO44194
)
anti-PD-1 monoclonal antibody
bispecific PD-1/LAG3 antibody
taxane
Breast cancer
VIC
3021 - St Albans - Western Health - Sunshine Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05805501
Advanced
Phase 2
paused
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (
BO43936
)
KIT inhibitor,ATP-competitive
VEGFR/PDGFR inhibitor
+ bispecific PD-1/LAG3 antibody
Clear cell renal cell carcinoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT05775289
Advanced
Phase 2
Active not recruiting
A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (
BO44178
)
anti-PD-1 monoclonal antibody
bispecific PD-1/LAG3 antibody
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05645692
Advanced
Phase 2
Not recruiting
A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy (
BO44157
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
bispecific PD-1/LAG3 antibody
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05419388
Advanced
Phase 1 / Phase 2
Not recruiting
A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (
BP43963
)
bispecific PD-1/LAG3 antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05116202
Advanced
Phase 1 / Phase 2
*paused
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (
BO43328
)
Atezolizumab
Ipilimumab
Nivolumab
RO7247669
Tiragolumab
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,TIGIT-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
+ bispecific PD-1/LAG3 antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
WA
6009 - Nedlands - Linear Clinical Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (2)
Active not recruiting (2)
Not recruiting (2)
paused (1)
*paused (1)
Recruitment Country and State
NSW (4)
NZ (3)
WA (3)
VIC (2)
QLD (2)
SA (2)
Phase
Phase 1 / Phase 2 (4)
Phase 2 (4)
Trial Type
Advanced (7)
Curative (1)
Cancer Therapy Class
LAG3
100%
PD-1
100%
PD-1/PD-L1
100%
TIGIT
63%
PD-L1
50%
VEGF
25%
CTLA4
25%
HIF2a
13%
IL-6
13%
PPAR-alpha
13%
KIT
13%
PDGFR
13%
VEGFR
13%
Facility
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
5112 - Elizabeth Vale - Lyell McEwin Hospital (2)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (2)
3021 - St Albans - Western Health - Sunshine Hospital (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
2109 - North Ryde - Macquarie University Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
6009 - Nedlands - One Clinical Research (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
Cancer Type
Cancer
Solid tumour
Gastrointestinal cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Upper gastrointestinal cancer
Urogenital cancer
Melanoma
Breast cancer
Clear cell renal cell carcinoma
Kidney cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Urothelial carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy